Commonwealth Equity Services, LLC Axogen, Inc. Transaction History

Commonwealth Equity Services, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$8.8 - $16.0 $205,048 - $372,816	-23,301 Closed	0 $0
Q3 2021 Oct 29, 2021	SELL	$15.23 - $21.72 $533 - $760	-35 Reduced 0.15%	23,301 $368,000
Q1 2021 May 04, 2021	SELL	$17.18 - $22.6 $6,872 - $9,040	-400 Reduced 1.69%	23,336 $472,000
Q4 2020 Feb 11, 2021	BUY	$11.5 - $17.96 $272,964 - $426,298	23,736 New	23,736 $424,000
Q2 2019 Jul 19, 2019	SELL	$18.5 - $25.47 $186,424 - $256,661	-10,077 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$14.62 - $22.13 $147,325 - $223,004	10,077 New	10,077 $212,000
Q4 2018 Feb 11, 2019	SELL	$17.09 - $38.25 $169,925 - $380,319	-9,943 Closed	0 $0
Q3 2018 Nov 06, 2018	BUY	$34.05 - $55.9 $18,489 - $30,353	543 Added 5.78%	9,943 $366,000
Q2 2018 Jul 31, 2018	SELL	$36.15 - $52.5 $99,051 - $143,850	-2,740 Reduced 22.57%	9,400 $472,000
Q1 2018 May 14, 2018	BUY	$24.4 - $40.25 $8,296 - $13,685	340 Added 2.88%	12,140 $443,000
Q4 2017 Feb 12, 2018	BUY	$18.5 - $28.6 $218,300 - $337,480	11,800	11,800 $334,000

163

36.6M

230K

400

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $763M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.